^
Association details:
| Biomarker: | CD73 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
Published date:
12/23/2020
Excerpt:
The baseline CD73 activity in patients with melanoma treated with nivolumab or pembrolizumab alone was significantly increased in patients with PD or SD compared with patients with CR or PR (p=0.0013; figure 2b).
DOI:
10.1136/jitc-2020-001689
